Calcipotriol/betamethasone aerosol foam (Enstilum) for the topical treatment of psoriasis vulgaris in routine practice in Korea: A prospective, noninterventional, multicenter study of treatment outcomes and patient satisfaction
- Authors
- Jo, Seong Jin; Park, Chul-Jong; Bang, Chul Hwan; Jeong, Ki-Heon; Shin, Bong Seok; Kim, Dong Hyun; Park, Hai-Jin; Kim, Byung-Soo; Song, Hae-Jun; Lee, Ju-Hee; Youn, Sang Woong
- Issue Date
- Nov-2022
- Publisher
- WILEY
- Keywords
- betamethasone dipropionate; calcipotriol drug combination; health-related quality of life; Korea; observational study; psoriasis
- Citation
- Journal of Dermatology, v.49, no.11, pp 1085 - 1095
- Pages
- 11
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of Dermatology
- Volume
- 49
- Number
- 11
- Start Page
- 1085
- End Page
- 1095
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61269
- DOI
- 10.1111/1346-8138.16519
- ISSN
- 0385-2407
1346-8138
- Abstract
- An innovative foam formulation for the fixed-dose combination of calcipotriol and betamethasone dipropionate (Cal/BD) has recently become available for the treatment of psoriasis vulgaris. Observational studies of patients treated with Cal/BD foam in routine practice have been conducted in several Western countries, but there are limited data on outcomes in Asian patients. We performed a prospective, open-label, noncomparative, noninterventional study to investigate treatment outcomes and satisfaction in adult patients receiving Cal/BD foam for psoriasis vulgaris in dermatological centers and outpatient clinics in Korea. Data were collected at the time of enrollment (Visit 1) and at a routine clinic visit similar to 4weeks later (Visit 2). In total, 218 patients were enrolled, of whom 175 were included in the safety analysis set (58.9% male; mean age+ standard deviation 46.7 +/- 15.1 years; use of Cal/BD foam at least once daily 74.3%). Of the safety analysis set, 166 patients had at least mild psoriasis (Investigator Global Assessment [IGA] <= 2) and were analyzed for treatment outcomes and satisfaction. Of the 166 patients, 71.7% had mild psoriasis (IGA 2) at baseline. The majority (57.8%) achieved an IGA of 0/1 (clear/almost clear) at Visit 2. The Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) showed significant improvements from Visit 1 to Visit 2 (PASI -2.4 +/- 3.0, DLQI -4.5 +/- 5.2, both P <0.0001). Most of the patients were satisfied with the Cal/BD foam treatment; 77.0%, 60.0%, and 73.9% were satisfied in terms of effectiveness, ease of use, and global satisfaction, respectively. In the safety analysis set, adverse events were reported in 13 patients (7.4%). In conclusion, this first Korean real-world study of Cal/BD foam shows improvement of lesions and health-related quality of life after 4weeks of treatment, with high global satisfaction and good overall tolerability and safety.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Dermatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.